Indaptus Therapeutics Inc. Common Stock (INDP)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I have always looked for businesses with durable earnings power, honest accounting, and a margin of safety. Indaptus does not fit that mold. It is a clinical-stage immunotherapy company with five employees and no reported revenue in the filed periods. Its lead candidate, Decoy20, may hold promise, but a pipeline is not a moat unless it produces approved products and cash flow. The financial record is stark: FY2025 net loss was $20.8M on EPS of -$21.58; FY2024 lost $15.0M; FY2023 lost $15.4M. In the fiscal Q2 2026 quarter ended 2026-06-30, the net loss was $1.8M, or -$0.02 per diluted share, but trailing free cash flow was -$14.7M. With a $7.1M market cap at the 2026-10-13 close of $2.39, FairStock's FCF yield is -206.7% and Altman Z-score is -1.93, a distress signal. FairStock Score is 22/100. P/B is 26.56, ROE -318.04%, ROCE -98.08%, and Piotroski F-score 1/9. FairStock's Lynch category is none, because the company has lost money in each of the last four years. The stock has traded between $0.92 and $5.96 over 52 weeks, which tells me the market is pricing hope, not proven value. Profit growth of 65.67% on FairStock's calculation may reflect narrowing quarterly losses, but one quarter does not create an investment-grade record. For a Graham-style investor, no earnings, negative cash flow and a tiny equity base leave no margin of safety. I would need to see revenue, sustained profit, and a much stronger balance sheet before calling this anything but speculative.

In plain English: Indaptus Therapeutics is a small drug development company with five employees working on immunotherapy treatments, including Decoy20. It has no reported revenue and has lost money in each of the last four years. At the 2026-10-13 close of $2.39, its $7.1 million total market value looks very high compared with its tiny accounting value and its cash losses, so the price does not look supported by current business numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer